Samsung Biologics expands global reach as CDMO demand grows

Samsung Biologics is strengthening its position in contract biologics manufacturing as global pharmaceutical companies seek more flexible production capacity. The stock reflects expectations for continued growth in biopharmaceutical outsourcing.

Samsung Biologics (ISIN KR7207940008) has become one of the leading contract development and manufacturing organizations in the biopharmaceutical industry, offering large-scale capacity to global drug makers that increasingly rely on outsourcing for complex biologic therapies.

The company focuses on manufacturing monoclonal antibodies and other biologic drugs under long-term contracts, giving pharmaceutical clients access to advanced facilities without committing their own capital to large-scale plants. For investors, the long-duration nature of these contracts can help underpin revenue visibility when biopharmaceutical demand is stable.

Biologics outsourcing gains momentum

Over the past years, drug makers have shifted more production of complex biologic medicines to specialized contract manufacturers, as clinical pipelines for antibody therapies, immunology treatments, and oncology drugs have expanded. Samsung Biologics has positioned itself as a key partner in this trend by operating modern, high-capacity plants designed specifically for biologic production.

The company offers end-to-end services spanning process development, scale-up, and commercial manufacturing, which can shorten timelines for bringing new biologic therapies to market. By combining large production lines with quality systems tailored to global regulatory standards, it aims to serve both established pharmaceutical companies and emerging biotech firms that may lack manufacturing infrastructure.

Capacity expansion and long-term contracts

To support additional demand, Samsung Biologics has invested heavily in new plants and capacity expansions, targeting large-volume biologic drugs as well as more specialized products. These facilities are built to accommodate multiple clients, with dedicated or semi-dedicated lines depending on contract structure, which allows the company to balance utilization and flexibility.

Long-term manufacturing agreements are common in this segment, as biologic therapies typically remain in production for years once approved. This structure can provide recurring revenue streams tied to product volumes, though contract manufacturing remains exposed to changes in client pipelines, competitive dynamics, and regulatory outcomes for specific drugs.

Representative service offering

One representative part of Samsung Biologics' business is its large-scale monoclonal antibody manufacturing service. These services cover cell line development, upstream and downstream processing, and fill-and-finish operations for injectable biologic products, aiming to meet global demand for therapies targeting autoimmune diseases, cancers, and other conditions.

Stock context

Samsung Biologics is listed on the Korea Exchange, giving investors exposure to the global biologics outsourcing theme via a South Korean issuer. The share price reflects expectations for continued growth in contract manufacturing and the company's ability to keep utilization high across its facilities.